therapies metabolism

International Brain Tumor Symposium 2010 – preliminary Program
March 23, 2010
Transfer from the airport, referent dinner
March 24, 2010
10.00h - 10.15h
Wolfgang Wick, Karl Plate und Joachim Steinbach
Scientific Organizing Committee
10.15h - 10.30h
Introduction: Current Issues in Neurooncology
Otmar Wiestler
Chairman and Scientific Director German Cancer Research Center
11.00 – 13.00h
Session 1: Individualizing brain tumor therapy
Chairs: W.K. Cavenee/
J.. Steinbach/
11.00 – 11.30h
Profiling malignant Glioma I: The genetic basis of the disease
Webster K .Cavenee
11.30 – 12.00h
Profiling malignant Glioma II: Implications for the design of molecular therapies
Tracy Batchelor
12.00h – 12.30h
Current clinical trials with molecular therapies
Wolfgang Wick
12.30 – 13.00h
Plenary Discussion: Individualizing molecular therapies
13.00h – 14.00h
Lunch Break
14.00h – 16.00
Session 2: Molecular & cellular pathology of gliomas Chairs: Andreas von
Deimling/ Ulrich Bogdahn
14.00 – 14.30h
Innovative techniques for high-throughput analyses
Peter Lichter
14.30 – 15.00h
Genetics of glioma progression and the definition of primary and secondary
Hiroko Ohgaki
15.00 – 15.30h
IDH1/2 mutations in gliomas
International Brain Tumor Symposium 2010 – preliminary Program
Andreas von Deimling
15.30 – 15.50h
Profiling of childhood brain tumors
Stefan Pfister
15.50h – 17.00h
Coffee Break and Poster Session
17.00 – 17.30h
The role of epigenetic alterations and miRNAs in glioma biology
17.30 – 18.00h
Mechanisms of cell death in gliomas I: Apoptosis
Simone Fulda
18.00 – 18.20h
Non-apoptotic functions of cell death-associated factors
Ana Martin-Villalba
18.20 – 18.40h
Mechanisms of cell death in gliomas II: Autophagy
Donat Kögel
18.40 – 19.00h
Plenary Discussion: Molecular Pathology
Business Meeting Frankfurt/Heidelberg Brain Tumor Research Consortium
International Brain Tumor Symposium 2010 – preliminary Program
March 25, 2010
8.00h – 10.30
Session 3: Glioma stem cells
8.00 – 8.30h
Glioblastoma stem cells: an organizational approach
Chairs: Roger McLendon/Andreas Trumpp
Roger McLendon
8.30 – 9.00h
Profiling of glioblastoma stem cell lines
Manfred Westphal
9.00 – 9.30h
The concept of stem cell dormancy
Andreas Trumpp
9.30 – 10.00h
Mechanisms and relevance of neural lineage differentiation in gliomas
Heidi Philips
10.00 – 10.30h
Plenary Discussion: Brain cancer stem cells
10.30h – 11.00h
Coffee Break
11.00h – 13.00h
Session 4: Angiogenesis and metabolism
Chair: Karl-H. Plate/Wolfgang
11.00h – 11.30h
Metabolism as a novel tumor-specific target of therapy
Thomas Seyfried
11.30h – 12.00h
Perspectives for the development of anti-angiogenic therapies
Karl Plate
12.00h – 12.30h
Hypoxia-induced resistance towards targeted therapies
Joachim Steinbach
12.30 – 13.00h
Plenary Discussion: Angiogenesis and metabolism
13.00h – 14.00h
14.00h – 16.30
Session 5: Virus and immune therapies for malignant gliomas
Michael Platten/Dorothee von Laer
14.00h – 14.30h
Gene therapy: current concepts and applications for glioma therapy
Christoph von Kalle
14.30h – 15.00h
Oncolytic virus therapy of glioblastoma with pseudotyped VSV vectors
International Brain Tumor Symposium 2010 – preliminary Program
Dorothee von Laer
15.00 – 15.20h
The role of tryptophan metabolites for glioma immune biology
Michael Platten
15.20 – 15.40h
Immunologic approaches towards glioma stem cells
Christel Herold-Mende
15.40 – 16.00h
Engineered measles virus as gene therapy for glioma
Guy Ungerechts
16.00h – 16.20h
Plenary Discussion: Virus and immune therapies for malignant glioma
16.20h – 17.00h
Coffee break
17.00h – 19.00h
Session 6: Selected short presentations
Andreas Unterberg
Evening Lecture
“The history of brain tumor research”
Paul Kleihues
Social Evening
Chair: Jörg-Christian Tonn/
International Brain Tumor Symposium 2010 – preliminary Program
March 26, 2010
8.30h – 11.15
Session 7: Brain tumor models
8.30 – 9.00h
Stem-like cells and the perivascular niche
Chairs: Manfred Westphal/Volker Seifert
Eric Holland
9.00 – 9.30h
Xenografting human gliomas from biopsy material: Current concepts
Rolf Bjerkvig
9.30 - 10.00h
Mechanisms and models for anti-Integrin therapy
Jörg-Christian Tonn
10.00 – 10.30h
Mechanisms of response and resistance to anti-VEGF therapy
Frank Winkler
13.00 – 11.00h
Novel therapeutic strategies for glioma patients after failure of bevacizumab
Lauren Abrey
11.00 – 11.15h
Plenary Discussion: Preclinical brain tumor models
11.15h – 11.30h
Coffee Break
11.30h – 12.00h
Session 8: Poster Prize Award
12.00h – 12.30h
Clinical practice lecture:
Chair: Michael Weller
Current standards of therapy for malignant gliomas and emerging concepts
Michael Weller
12.30 – 13.00h
Plenary Discussion: Current standards of therapy
13.00h – 13.15h
Closing remarks and summary
Wolfgang Wick, Karl Plate und Joachim Steinbach
13.15h – 14.00h
Lunch buffet & departures
14.00 – 15.30h
Steering Committee Frankfurt/Heidelberg Brain Tumor Research Consortium
International Brain Tumor Symposium 2010 – preliminary Program
Platinum Sponsors
Gold Sponsors
Silver Sponsors
Merck, Essex
Boehringer Ingelheim, Lilly, Novartis,
Sigma-Tau, Mundipharma